Press Release
<p>FERRING PHARMACEUTICALS OBTAINS RIGHTS TO EUFLEXXA™</p>
<p><strong>Enters Co-Promotion Agreement with Savient</strong> </p>
<table class="newsroom">
<tr>
<td valign="top" width="57"><p><b>Contact:</b></p></td>
<td width="20" valign="top"></td>
<td width="304">
<p>Kelly Laban<br>
Kovak-Likly Communications<br>
(203)762-8833 x15 or KLaban@KLCpr.com</p>
</td>
</tr>
</table>
<p>Suffern, NY – July 19, 2005 –
Ferring Pharmaceuticals Inc. announced today that it has entered into an
agreement to market EUFLEXXA™, a novel, non-avian-derived biologic formulation of hyaluronic acid for the
amelioration of knee pain due to osteoarthritis. This agreement forms part of a
broader transaction whereby the Ferring Group acquired the global biologics
manufacturing business of Savient Pharmaceuticals, Inc., including the worldwide
rights to EUFLEXXA. </p>
<p>“This agreement represents an additional specialty
marketing opportunity that expands our product line beyond infertility,” said
Wayne Anderson, president of Ferring Pharmaceuticals. “It is in keeping with
our corporate strategy of niche marketing specialty products with manageable
physician prescribing audiences.” </p>
<p>EUFLEXXA is the first and only non-avian-derived biologic formulation of hyaluronic acid
approved in the U.S. for osteoarthritis of the knee. Under the agreement,
Ferring and Savient, the developers of the product, will jointly market EUFLEXXA,
which is expected to launch in Q4 2005. Ferring will be forming a specialist
field force for this purpose. </p>
<p><strong>About Ferring Pharmaceuticals Inc.</strong><br/>
Ferring Pharmaceuticals Inc., part of the
Ferring Group, a privately owned, international pharmaceutical company, markets
Menopur<sup><sup>®</sup></sup> (menotropins for injection, USP), Bravelle<sup><sup>®</sup></sup>
(urofollitropin for injection, purified), Repronex<sup><sup>®</sup></sup> (menotropins for injection, USP)<sup> </sup>and
Novarel<sup><sup>®</sup></sup> (chorionic gonadotropin for injection, USP)
in the U.S. to infertility specialists and their patients. Ferring also offers
the Q∙CAP™, the first and only needle-free reconstitution device, for
use with its fertility treatments. The Ferring Group specializes in the
research, development and commercialization of compounds in general and
pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and
infertility. For more information, visit
<a href="http://www.ferringusa.com/">www.ferringusa.com</a>. </p>
<p># # # </p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
Patient Treatment Information
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
